Saturday, October 19, 2019
News
NEWS HOME
Ľ
PRESS RELEASES

Independent large real-world study comparing NOACs in AF-patients
  SocialTwist Tell-a-Friend  
   


Date: 15-04-2019 12:54PM
Source: Boehringer Ingelheim
Category: Business/ Finance, Pharmaceutical, General, Science & Research, Healthcare & Biotechnology
Location: Ingelheim, Germany

Business Wire India

  • A recently published large retrospective comparative study investigated stroke, bleeding and mortality risks in older US Medicare patients treated with commonly marketed oral anticoagulants for non-valvular atrial fibrillation1
  • Results of the real-world study showed that Pradaxa® (dabigatran etexilate) was associated with a more favourable benefit-risk profile in comparison to both warfarin and rivaroxaban1
  • Data from an earlier FDA-funded Medicare study published in 2015, which investigated cardiovascular, bleeding and mortality risks among patients treated with dabigatran compared to warfarin, have recently led to a positive label update for Pradaxa® in the EU


The results from an independent retrospective comparative study, published in January 2019 in the American Journal of Medicine, showed that dabigatran was associated with a more favourable benefit-harm profile than both warfarin and rivaroxaban. The study analysed a database of patients enrolled in US Medicare with non-valvular atrial fibrillation (NVAF) treated with either a standard dose of a non-vitamin K antagonist oral anticoagulants (NOAC, i.e. dabigatran, rivaroxaban or apixaban) or warfarin.1

Recently, the Summary of Product Characteristics (SmPC) for dabigatran in the EU was updated with information from the results of a previous large independent Medicare study, which was published in Circulation in 2015. In the study, dabigatran was associated with reduced risk of ischaemic stroke, intracranial haemorrhage and mortality and increased risk of gastrointestinal bleeding in elderly NVAF patients compared to warfarin. The risk of major bleeding was similar across both study drugs.2

According to the 2019 independent real-world study, compared to warfarin, each NOAC investigated was associated with reduced risk of thromboembolic stroke (20-29% reduction; P=0.002 [dabigatran], P<0.001 [rivaroxaban, apixaban]), intracranial haemorrhage (35-62% reduction; P<0.001 [each NOAC]), and mortality (19-34% reduction; P<0.001 [each NOAC]).1

The most recent study also compared the individual NOACs with each other. According to the results, both dabigatran and apixaban demonstrated decreased risks of intracranial haemorrhage, major extracranial bleeding, and death, compared with rivaroxaban.1

Overall, the authors concluded that among the NOACs, apixaban and dabigatran had a more favourable benefit-harm profile than rivaroxaban.1

“This independent study from 2019 is a positive reminder of dabigatran’s demonstrated safety profile, compared to both warfarin and rivaroxaban,” said Dr Waheed Jamal, Corporate Vice President, Head of Cardiometabolic Medicine, Boehringer Ingelheim. “Also, it is quite unique that a non-interventional study based on a retrospective assessment of a specific database has been accepted by a Health Authority to be added to the product label. Both this and the new comparative data add further credibility to the body of evidence demonstrating the favourable safety and efficacy profile of Pradaxa® in its licensed indications.”

The 2019 study was carried out by independent researchers including David J. Graham, MD, MPHm, and funded by US Food and Drug Administration (FDA). The retrospective, propensity-matched study analysed data from NVAF patients (≥ 65 years old) enrolled in US Medicare between Oct. 2010 and Sept. 2015. Only those initiating on warfarin (183,318) or standard US dose of dabigatran (86,198), rivaroxaban (106,389), or apixaban (73,039) were included.

The 2015 study was also carried out by independent researchers, led by David J. Graham, MD, MPHm, and was funded through an intra-agency agreement between the Centers for Medicare & Medicaid Services and the FDA. The retrospective study analysed data from NVAF patients (≥ 65 years old) initiating dabigatran or warfarin for the treatment of nonvalvular AF, who were enrolled in US Medicare between Oct. 2010 and Dec. 2012. Dabigatran users (67,207) were propensity score matched to warfarin users in a 1:1 ratio. Patients who had received prior treatment with a study medication or rivaroxaban or apixaban were excluded from the study.

Please click on the following link for ‘Notes to Editors’ and ‘References’: http://www.boehringer-ingelheim.com/press-release/real-world-study-comparing-noacs-af-patients

Intended audiences:
This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. It is directed to the international audience outside Germany. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.



CONTACTS :

Media Contact
Boehringer Ingelheim
Corporate Communications
Media + PR
Meike Bausinger
55216 Ingelheim/Germany
Phone: +49 6132 77 182085
Mobile: +49 151 44061760
Fax: +49 6132 77 6601
Email: press@boehringer-ingelheim.com

More Press Releases

Dive In: The Festival for Diversity and Inclusion in Insurance

BUSINESS ENGINEER Enables 4x Ecommerce Business Growth for KEYA Foods on Completion of Phase-I Order Fulfillment Project

Professor Michael E. Porter Addresses the Gathering at Porter Prize 2019

Schlumberger Announces Third-Quarter 2019 Results

CDIB Capital Group Appoints Mr. Angelo J.Y. Koo as Chairman to Lead Global Asset Management Business

L&T Technology Services Continues Double-Digit Revenue Growth in Q2FY20

VARU - the 5th Tropical Resort by Atmosphere Hotels & Resorts Launched in the North-West of Maldives on 17th October 2019

Kalpataru Launches Integrated Mixed Use Township Kalpataru Parkcity in Thane

#JustEMI to Fulfil All Your Aspirations This Diwali and Shop Without Compromise With Bajaj Finserv

Frost & Sullivanís GIL 2019: India Aimed to Uncover the Next Wave of Sustainable Top-Line Revenue Growth, Customer Value, and Future of the Connected World

The Hero Campus Challenge Returns to Nurture the Business Leaders of Tomorrow

Vakilsearch Signs MoU With the Largest Dutch Legal-Tech Company

Make Your Diwali Thrilling with RummyBaazi.com

The 46th Tokyo Motor Show 2019: Events and Programs News Update

Pioneer Cement of UAE to Develop US$200 Million Greenfield Cement Project in Georgia

FlowerAura Launches Profile Picture Worthy Bhai Dooj Gifts for 2019

Secure Your New Smartphone With Mobile Screen Insurance From Bajaj Finserv

Mavenir Confirmed as Global Leader in NFV-based IMS Solutions

Andersen Global Expands in India With Membership of Nangia Andersen LLP

Lookout App Defense Penetrates Global Markets With New Customers and Strategic Partnerships, Helping Customers Prevent Data Compromise in Mobile Apps

PTC Launches Global Event Series with FT Live to Help Industrial Enterprises Embrace Digital Transformation

Historic Conrad Hilton Bel-Air Estate Hits Market for $225 Million

 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
INDIA WORLD ASIA
It's Congress VS Congress in R'sthan ove...
40,000 indigenous bulletproof jackets su...
Salman Khan's aide Shera joins Shiv Sena...
Obesity rates soar due to dramatic globa...
H1B visa norms tightened, Indian techies...
7 held for running call centres that dup...
More...    
 
 Top Stories
FATF keeps Pak in grey list, hands ... 
Criminals snatch mobile of Delhi As... 
Corrupt Congress-NCP did maximum ha... 
Policy space exists to address grow... 
Bridge across Shyok River to be nam... 
BJP, BJD in verbal duel ahead of Bi... 
Anup K. Singh appointed new Nationa... 
Fresh stock to bring onion prices d...